Kathleen Moore to Molecular Targeted Therapy
This is a "connection" page, showing publications Kathleen Moore has written about Molecular Targeted Therapy.
Connection Strength
0.947
-
Niraparib in the treatment of previously treated advanced ovarian, fallopian tube or primary peritoneal cancer. Future Oncol. 2020 Nov; 16(33):2701-2711.
Score: 0.629
-
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecol Oncol. 2020 09; 158(3):640-645.
Score: 0.155
-
Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecol Oncol. 2018 03; 148(3):591-600.
Score: 0.131
-
Characterization of folate receptor alpha (FRa) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRa-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017 11; 147(2):402-407.
Score: 0.032